09:05am Wednesday 18 July 2018

Genetic defect makes malignant smooth muscle tumors vulnerable

A research team under the leadership of scientists from the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelberg have conducted the first comprehensive analysis of the genome of malignant smooth muscle tumors. In a high percentage of tumors, they discovered a weak spot in the genome of the cancer cells that may serve as a therapy target in the future.

Leiomyosarcoma is a type of cancer of the smooth muscles that can arise almost anywhere in the body. Common places are the uterus, the abdomen or the muscles of the blood vessels. Even the tiny muscles that make our hair stand on end can be affected.

Like most other types of sarcoma, leiomyosarcomas respond very poorly to chemotherapy. In many cases, surgery and radiotherapy are the only effective treatment options. “Unfortunately, many tumors recur despite radical surgery or have already spread in the body,” said Stefan Fröhling, an oncologist who works at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), the National Center for Tumor Diseases (NCT) Heidelberg and Heidelberg University Hospital.

Leiomyosarcoma is a very rare type of cancer. Only about 150 to 200 cases are diagnosed each year in Germany. Therefore, little is known to date about its molecular causes. In collaboration with other partner sites of the German Cancer Consortium (DKTK) as well as partners in Mannheim and Rotterdam, Fröhling and his colleagues have now been the first to study the genetic causes of leiomyosarcoma in a comprehensive analysis of tumor samples from 49 patients. The researchers sequenced the tumor genomes and analyzed the genes that showed particular activity. “An analysis of this kind would not have been possible at a single hospital,” Fröhling said. “One of our goals was to find specific alterations that can be used to attack the cancer cells using targeted drugs.”

The researchers found a state of complete chaos in the genome of leiomyosarcoma. In many cases, large parts of the genome were missing or were present in multiple copies. In some cases, the whole genome had doubled or even tripled. In particular, the investigators noticed that the two most important cancer brakes, tumor suppressor genes TP53 and RB1, were absent in extremely many cases. In over 90 percent of the samples under investigation, both of their gene copies had been destroyed.

The analysis also revealed how the tumor cells acquire immortality. In over 75 percent of the cases studied, the cancer cells had found different ways of lengthening their telomeres. In healthy cells, the length of these structures on the ends of chromosomes limits the number of possible divisions.

The scientists also made an encouraging discovery: In most tumors, they found evidence suggesting that an important DNA repair system known as homologous recombination had been disrupted. As a result, the cancer cells become sensitive to substances that destroy DNA such as certain chemotherapy agents. Another tactic for cancer cells with this type of mutation is to use substances called PARP inhibitors to disable also the other key cellular DNA repair system. “Then the cancer cells die from their genomic defects,” explained Claudia Scholl from DKFZ, who led the investigation jointly with Fröhling.

The researchers have already been able to confirm this theory in leiomyosarcoma cells in the Petri dish. “First clinical trials will examine whether this approach is effective in bone sarcoma,” Scholl said. “We have found a starting point which we might be able to use to better help people with leiomyosarcoma in the future,” the scientist said.

Priya Chudasama, Sadaf S. Mughal, Mathijs A. Sanders, Daniel Hübschmann, Inn Chung, Katharina I. Deeg, Siao-Han Wong, Sophie Rabe, Mario Hlevnjak, Marc Zapatka, Aurélie Ernst, Kortine Kleinheinz, Matthias Schlesner, Lina Sieverling, Barbara Klink, Evelin Schröck, Remco M. Hoogenboezem, Bernd Kasper, Christoph E. Heilig, Gerlinde, Egerer, Stephan Wolf, Christof von Kalle, Roland Eils, Albrecht Stenzinger, Wilko Weichert, Hanno Glimm, Stefan Gröschel, Hans-Georg Kopp, Georg Omlor, Burkhard Lehner, Sebastian Bauer, Simon Schimmack, Alexis Ulrich, Gunhild Mechtersheimer, Karsten Rippe, Benedikt Brors, Barbara Hutter, Marcus Renner, Peter Hohenberger, Claudia Scholl & Stefan Fröhling: Integrative genomic and transcriptomic analysis of leiomyosarcoma
Nature Communications 2018, DOI: 10.1038/s41467-017-02602-0

 

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

 

 


Share on:
or:

Health news